Loading…
Metabolomic profiles in relapsing–remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study
Introduction and objectives Multiple sclerosis (MS) is a disease of the central nervous system associated with immune dysfunction, demyelination, and neurodegeneration. The disease has heterogeneous clinical phenotypes such as relapsing–remitting MS (RRMS) and progressive multiple sclerosis (PMS), e...
Saved in:
| Published in: | Metabolomics 2023-04, Vol.19 (5), p.44-44, Article 44 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c326t-4a02eedbf75da22c14325153974ec95dfd0aba538593abe8f4cf049c6d85a92c3 |
| container_end_page | 44 |
| container_issue | 5 |
| container_start_page | 44 |
| container_title | Metabolomics |
| container_volume | 19 |
| creator | Shi, Tiange Browne, Richard W. Tamaño-Blanco, Miriam Jakimovski, Dejan Weinstock-Guttman, Bianca Zivadinov, Robert Ramanathan, Murali Blair, Rachael H. |
| description | Introduction and objectives
Multiple sclerosis (MS) is a disease of the central nervous system associated with immune dysfunction, demyelination, and neurodegeneration. The disease has heterogeneous clinical phenotypes such as relapsing–remitting MS (RRMS) and progressive multiple sclerosis (PMS), each with unique pathogenesis. Metabolomics research has shown promise in understanding the etiologies of MS disease. However, there is a paucity of clinical studies with follow-up metabolomics analyses. This 5-year follow-up (5YFU) cohort study aimed to investigate the metabolomics alterations over time between different courses of MS patients and healthy controls and provide insights into metabolic and physiological mechanisms of MS disease progression.
Methods
A cohort containing 108 MS patients (37 PMS and 71 RRMS) and 42 controls were followed up for a median of 5 years. Liquid chromatography–mass spectrometry (LC–MS) was applied for untargeted metabolomics profiling of serum samples of the cohort at both baseline and 5YFU. Univariate analyses with mixed-effect ANCOVA models, clustering, and pathway enrichment analyses were performed to identify patterns of metabolites and pathway changes across the time effects and patient groups.
Results and conclusions
Out of 592 identified metabolites, the PMS group exhibited the most changes, with 219 (37%) metabolites changed over time and 132 (22%) changed within the RRMS group (Bonferroni adjusted P |
| doi_str_mv | 10.1007/s11306-023-02010-0 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2803964344</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2803964344</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-4a02eedbf75da22c14325153974ec95dfd0aba538593abe8f4cf049c6d85a92c3</originalsourceid><addsrcrecordid>eNp9kU2P1SAUhhujccbRP-DCkLhxUz18tBR3ZuJXMsaNrgmF0ztMaKlAx9yda7f-Q3-JXO_4EReGEE7ged8DvE3zkMJTCiCfZUo59C0wXidQaOFWc0o7yVs-KLj9V33S3Mv5CkAIJeFuc8IlSMV6etp8fYfFjDHE2Vuypjj5gJn4hSQMZs1-2X3_8i3h7EupNTGLO1C7hDn7ayTzFopfA5JsA6aYfSY2zqtJ6EiJ5BJNKJf7ureUFEN-TgyZqq7do0lkiiHEz-22klw2t7_f3JlMyPjgZj1rPr56-eH8TXvx_vXb8xcXreWsL60wwBDdOMnOGcYsFZx1tONKCrSqc5MDM5qOD53iZsRhEnYCoWzvhs4oZvlZ8-ToWx_yacNc9OyzxRDMgnHLmg3AVS-4EBV9_A96Fbe01NsdKKnqkAeKHSlbfyAnnPSa_GzSXlPQh6T0MSldk9I_k9JQRY9urLdxRvdb8iuaCvAjkOvRssP0p_d_bH8AaSaioA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2807979774</pqid></control><display><type>article</type><title>Metabolomic profiles in relapsing–remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study</title><source>Springer Nature</source><creator>Shi, Tiange ; Browne, Richard W. ; Tamaño-Blanco, Miriam ; Jakimovski, Dejan ; Weinstock-Guttman, Bianca ; Zivadinov, Robert ; Ramanathan, Murali ; Blair, Rachael H.</creator><creatorcontrib>Shi, Tiange ; Browne, Richard W. ; Tamaño-Blanco, Miriam ; Jakimovski, Dejan ; Weinstock-Guttman, Bianca ; Zivadinov, Robert ; Ramanathan, Murali ; Blair, Rachael H.</creatorcontrib><description>Introduction and objectives
Multiple sclerosis (MS) is a disease of the central nervous system associated with immune dysfunction, demyelination, and neurodegeneration. The disease has heterogeneous clinical phenotypes such as relapsing–remitting MS (RRMS) and progressive multiple sclerosis (PMS), each with unique pathogenesis. Metabolomics research has shown promise in understanding the etiologies of MS disease. However, there is a paucity of clinical studies with follow-up metabolomics analyses. This 5-year follow-up (5YFU) cohort study aimed to investigate the metabolomics alterations over time between different courses of MS patients and healthy controls and provide insights into metabolic and physiological mechanisms of MS disease progression.
Methods
A cohort containing 108 MS patients (37 PMS and 71 RRMS) and 42 controls were followed up for a median of 5 years. Liquid chromatography–mass spectrometry (LC–MS) was applied for untargeted metabolomics profiling of serum samples of the cohort at both baseline and 5YFU. Univariate analyses with mixed-effect ANCOVA models, clustering, and pathway enrichment analyses were performed to identify patterns of metabolites and pathway changes across the time effects and patient groups.
Results and conclusions
Out of 592 identified metabolites, the PMS group exhibited the most changes, with 219 (37%) metabolites changed over time and 132 (22%) changed within the RRMS group (Bonferroni adjusted P < 0.05). Compared to the baseline, there were more significant metabolite differences detected between PMS and RRMS classes at 5YFU. Pathway enrichment analysis detected seven pathways perturbed significantly during 5YFU in MS groups compared to controls. PMS showed more pathway changes compared to the RRMS group.</description><identifier>ISSN: 1573-3890</identifier><identifier>ISSN: 1573-3882</identifier><identifier>EISSN: 1573-3890</identifier><identifier>DOI: 10.1007/s11306-023-02010-0</identifier><identifier>PMID: 37079261</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Cell Biology ; Central nervous system ; Cohort Studies ; Demyelination ; Developmental Biology ; Follow-Up Studies ; Humans ; Life Sciences ; Liquid chromatography ; Mass spectroscopy ; Metabolites ; Metabolomics ; Molecular Medicine ; Multiple Sclerosis ; Multiple Sclerosis, Chronic Progressive ; Neurodegeneration ; Original Article ; Phenotypes</subject><ispartof>Metabolomics, 2023-04, Vol.19 (5), p.44-44, Article 44</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-4a02eedbf75da22c14325153974ec95dfd0aba538593abe8f4cf049c6d85a92c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37079261$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shi, Tiange</creatorcontrib><creatorcontrib>Browne, Richard W.</creatorcontrib><creatorcontrib>Tamaño-Blanco, Miriam</creatorcontrib><creatorcontrib>Jakimovski, Dejan</creatorcontrib><creatorcontrib>Weinstock-Guttman, Bianca</creatorcontrib><creatorcontrib>Zivadinov, Robert</creatorcontrib><creatorcontrib>Ramanathan, Murali</creatorcontrib><creatorcontrib>Blair, Rachael H.</creatorcontrib><title>Metabolomic profiles in relapsing–remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study</title><title>Metabolomics</title><addtitle>Metabolomics</addtitle><addtitle>Metabolomics</addtitle><description>Introduction and objectives
Multiple sclerosis (MS) is a disease of the central nervous system associated with immune dysfunction, demyelination, and neurodegeneration. The disease has heterogeneous clinical phenotypes such as relapsing–remitting MS (RRMS) and progressive multiple sclerosis (PMS), each with unique pathogenesis. Metabolomics research has shown promise in understanding the etiologies of MS disease. However, there is a paucity of clinical studies with follow-up metabolomics analyses. This 5-year follow-up (5YFU) cohort study aimed to investigate the metabolomics alterations over time between different courses of MS patients and healthy controls and provide insights into metabolic and physiological mechanisms of MS disease progression.
Methods
A cohort containing 108 MS patients (37 PMS and 71 RRMS) and 42 controls were followed up for a median of 5 years. Liquid chromatography–mass spectrometry (LC–MS) was applied for untargeted metabolomics profiling of serum samples of the cohort at both baseline and 5YFU. Univariate analyses with mixed-effect ANCOVA models, clustering, and pathway enrichment analyses were performed to identify patterns of metabolites and pathway changes across the time effects and patient groups.
Results and conclusions
Out of 592 identified metabolites, the PMS group exhibited the most changes, with 219 (37%) metabolites changed over time and 132 (22%) changed within the RRMS group (Bonferroni adjusted P < 0.05). Compared to the baseline, there were more significant metabolite differences detected between PMS and RRMS classes at 5YFU. Pathway enrichment analysis detected seven pathways perturbed significantly during 5YFU in MS groups compared to controls. PMS showed more pathway changes compared to the RRMS group.</description><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cell Biology</subject><subject>Central nervous system</subject><subject>Cohort Studies</subject><subject>Demyelination</subject><subject>Developmental Biology</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Liquid chromatography</subject><subject>Mass spectroscopy</subject><subject>Metabolites</subject><subject>Metabolomics</subject><subject>Molecular Medicine</subject><subject>Multiple Sclerosis</subject><subject>Multiple Sclerosis, Chronic Progressive</subject><subject>Neurodegeneration</subject><subject>Original Article</subject><subject>Phenotypes</subject><issn>1573-3890</issn><issn>1573-3882</issn><issn>1573-3890</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kU2P1SAUhhujccbRP-DCkLhxUz18tBR3ZuJXMsaNrgmF0ztMaKlAx9yda7f-Q3-JXO_4EReGEE7ged8DvE3zkMJTCiCfZUo59C0wXidQaOFWc0o7yVs-KLj9V33S3Mv5CkAIJeFuc8IlSMV6etp8fYfFjDHE2Vuypjj5gJn4hSQMZs1-2X3_8i3h7EupNTGLO1C7hDn7ayTzFopfA5JsA6aYfSY2zqtJ6EiJ5BJNKJf7ureUFEN-TgyZqq7do0lkiiHEz-22klw2t7_f3JlMyPjgZj1rPr56-eH8TXvx_vXb8xcXreWsL60wwBDdOMnOGcYsFZx1tONKCrSqc5MDM5qOD53iZsRhEnYCoWzvhs4oZvlZ8-ToWx_yacNc9OyzxRDMgnHLmg3AVS-4EBV9_A96Fbe01NsdKKnqkAeKHSlbfyAnnPSa_GzSXlPQh6T0MSldk9I_k9JQRY9urLdxRvdb8iuaCvAjkOvRssP0p_d_bH8AaSaioA</recordid><startdate>20230420</startdate><enddate>20230420</enddate><creator>Shi, Tiange</creator><creator>Browne, Richard W.</creator><creator>Tamaño-Blanco, Miriam</creator><creator>Jakimovski, Dejan</creator><creator>Weinstock-Guttman, Bianca</creator><creator>Zivadinov, Robert</creator><creator>Ramanathan, Murali</creator><creator>Blair, Rachael H.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20230420</creationdate><title>Metabolomic profiles in relapsing–remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study</title><author>Shi, Tiange ; Browne, Richard W. ; Tamaño-Blanco, Miriam ; Jakimovski, Dejan ; Weinstock-Guttman, Bianca ; Zivadinov, Robert ; Ramanathan, Murali ; Blair, Rachael H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-4a02eedbf75da22c14325153974ec95dfd0aba538593abe8f4cf049c6d85a92c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cell Biology</topic><topic>Central nervous system</topic><topic>Cohort Studies</topic><topic>Demyelination</topic><topic>Developmental Biology</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Liquid chromatography</topic><topic>Mass spectroscopy</topic><topic>Metabolites</topic><topic>Metabolomics</topic><topic>Molecular Medicine</topic><topic>Multiple Sclerosis</topic><topic>Multiple Sclerosis, Chronic Progressive</topic><topic>Neurodegeneration</topic><topic>Original Article</topic><topic>Phenotypes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shi, Tiange</creatorcontrib><creatorcontrib>Browne, Richard W.</creatorcontrib><creatorcontrib>Tamaño-Blanco, Miriam</creatorcontrib><creatorcontrib>Jakimovski, Dejan</creatorcontrib><creatorcontrib>Weinstock-Guttman, Bianca</creatorcontrib><creatorcontrib>Zivadinov, Robert</creatorcontrib><creatorcontrib>Ramanathan, Murali</creatorcontrib><creatorcontrib>Blair, Rachael H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Metabolomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shi, Tiange</au><au>Browne, Richard W.</au><au>Tamaño-Blanco, Miriam</au><au>Jakimovski, Dejan</au><au>Weinstock-Guttman, Bianca</au><au>Zivadinov, Robert</au><au>Ramanathan, Murali</au><au>Blair, Rachael H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolomic profiles in relapsing–remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study</atitle><jtitle>Metabolomics</jtitle><stitle>Metabolomics</stitle><addtitle>Metabolomics</addtitle><date>2023-04-20</date><risdate>2023</risdate><volume>19</volume><issue>5</issue><spage>44</spage><epage>44</epage><pages>44-44</pages><artnum>44</artnum><issn>1573-3890</issn><issn>1573-3882</issn><eissn>1573-3890</eissn><abstract>Introduction and objectives
Multiple sclerosis (MS) is a disease of the central nervous system associated with immune dysfunction, demyelination, and neurodegeneration. The disease has heterogeneous clinical phenotypes such as relapsing–remitting MS (RRMS) and progressive multiple sclerosis (PMS), each with unique pathogenesis. Metabolomics research has shown promise in understanding the etiologies of MS disease. However, there is a paucity of clinical studies with follow-up metabolomics analyses. This 5-year follow-up (5YFU) cohort study aimed to investigate the metabolomics alterations over time between different courses of MS patients and healthy controls and provide insights into metabolic and physiological mechanisms of MS disease progression.
Methods
A cohort containing 108 MS patients (37 PMS and 71 RRMS) and 42 controls were followed up for a median of 5 years. Liquid chromatography–mass spectrometry (LC–MS) was applied for untargeted metabolomics profiling of serum samples of the cohort at both baseline and 5YFU. Univariate analyses with mixed-effect ANCOVA models, clustering, and pathway enrichment analyses were performed to identify patterns of metabolites and pathway changes across the time effects and patient groups.
Results and conclusions
Out of 592 identified metabolites, the PMS group exhibited the most changes, with 219 (37%) metabolites changed over time and 132 (22%) changed within the RRMS group (Bonferroni adjusted P < 0.05). Compared to the baseline, there were more significant metabolite differences detected between PMS and RRMS classes at 5YFU. Pathway enrichment analysis detected seven pathways perturbed significantly during 5YFU in MS groups compared to controls. PMS showed more pathway changes compared to the RRMS group.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>37079261</pmid><doi>10.1007/s11306-023-02010-0</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1573-3890 |
| ispartof | Metabolomics, 2023-04, Vol.19 (5), p.44-44, Article 44 |
| issn | 1573-3890 1573-3882 1573-3890 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2803964344 |
| source | Springer Nature |
| subjects | Biochemistry Biomedical and Life Sciences Biomedicine Cell Biology Central nervous system Cohort Studies Demyelination Developmental Biology Follow-Up Studies Humans Life Sciences Liquid chromatography Mass spectroscopy Metabolites Metabolomics Molecular Medicine Multiple Sclerosis Multiple Sclerosis, Chronic Progressive Neurodegeneration Original Article Phenotypes |
| title | Metabolomic profiles in relapsing–remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A51%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolomic%20profiles%20in%20relapsing%E2%80%93remitting%20and%20progressive%20multiple%20sclerosis%20compared%20to%20healthy%20controls:%20a%20five-year%20follow-up%20study&rft.jtitle=Metabolomics&rft.au=Shi,%20Tiange&rft.date=2023-04-20&rft.volume=19&rft.issue=5&rft.spage=44&rft.epage=44&rft.pages=44-44&rft.artnum=44&rft.issn=1573-3890&rft.eissn=1573-3890&rft_id=info:doi/10.1007/s11306-023-02010-0&rft_dat=%3Cproquest_cross%3E2803964344%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c326t-4a02eedbf75da22c14325153974ec95dfd0aba538593abe8f4cf049c6d85a92c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2807979774&rft_id=info:pmid/37079261&rfr_iscdi=true |